NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471

Active Not RecruitingPhase 2

Sponsor: Janssen Research & Development, LLC

Conditions: Crohn's Disease

Interventions: Guselkumab, Golimumab, JNJ-78934804, Placebo

Countries: United States, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of Crohn's disease (CD) for at least 3 months prior to baseline
* Confirmed diagnosis of moderate to severe CD as assessed by Crohn'

Locations (456)

Birmingham, Alabama, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Apple Valley, California, United States
Arcadia, California, United States
Coronado, California, United States
Lancaster, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Newport Beach, California, United States
Orange, California, United States
San Diego, California, United States
San Francisco, California, United States
Aurora, Colorado, United States
Hamden, Connecticut, United States
New Haven, Connecticut, United States
Washington D.C., District of Columbia, United States
Coconut Creek, Florida, United States
Homestead, Florida, United States
Kissimmee, Florida, United States
Lakewood Rch, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Orlando, Florida, United States
St. Petersburg, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Macon, Georgia, United States
Marietta, Georgia, United States
+ 426 more on CT.gov